skip to main content
Idioma:

A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study

Levine, John E, Prof ; Braun, Thomas M, Prof ; Harris, Andrew C, MD ; Holler, Ernst, MD ; Taylor, Austin, BA ; Miller, Holly, DO ; Magenau, John, MD ; Weisdorf, Daniel J, Prof ; Ho, Vincent T, MD ; Bolaños-Meade, Javier, MD ; Alousi, Amin M, MD ; Ferrara, James L M, Prof

The Lancet. Haematology, 2015, Vol.2 (1), p.e21-e29 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
  • Título:
    A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study
  • Autor: Levine, John E, Prof ; Braun, Thomas M, Prof ; Harris, Andrew C, MD ; Holler, Ernst, MD ; Taylor, Austin, BA ; Miller, Holly, DO ; Magenau, John, MD ; Weisdorf, Daniel J, Prof ; Ho, Vincent T, MD ; Bolaños-Meade, Javier, MD ; Alousi, Amin M, MD ; Ferrara, James L M, Prof
  • Assuntos: Adolescent ; Adult ; Aged ; Biomarkers - blood ; Child ; Child, Preschool ; Graft vs Host Disease - diagnosis ; Graft vs Host Disease - drug therapy ; Graft vs Host Disease - mortality ; Hematology, Oncology and Palliative Medicine ; Hematopoietic Stem Cell Transplantation - adverse effects ; Humans ; Infant ; Infant, Newborn ; Middle Aged ; Prognosis ; Transplantation, Homologous - adverse effects ; Young Adult
  • É parte de: The Lancet. Haematology, 2015, Vol.2 (1), p.e21-e29
  • Notas: ObjectType-Article-1
    SourceType-Scholarly Journals-1
    ObjectType-News-2
    ObjectType-Feature-3
    content type line 23
  • Descrição: Summary Background Graft-versus-host disease (GVHD) is the major cause of non-relapse mortality after allogeneic haemopoietic stem-cell transplantation (SCT). The severity of symptoms at the onset of GVHD does not accurately define risk, and thus most patients are treated alike with high dose systemic corticosteroids. We aimed to define clinically meaningful risk strata for patients with newly diagnosed acute GVHD using plasma biomarkers. Methods Between April 13, 2000, and May 7, 2013, we prospectively collected plasma from 492 SCT patients with newly diagnosed acute GVHD and randomly assigned (2:1) using a random number generator, conditional on the final two datasets having the same median day of onset, into training (n=328) and test (n=164) sets. We used the concentrations of three recently validated biomarkers (TNFR1, ST2, and Reg3α) to create an algorithm that computed the probability of non-relapse mortality 6 months after GVHD onset for individual patients in the training set alone. We rank ordered the probabilities and identified thresholds that created three distinct non-relapse mortality scores. We evaluated the algorithm in the test set, and again in an independent validation set of an additional 300 patients who underwent stem cell transplant and were enrolled on multicentre clinical trials of primary therapy for acute GVHD. Findings In all three datasets (training, test, and validation), the cumulative incidence of 6-month non-relapse mortality significantly increased as the Ann Arbor GVHD score increased. In the multicentre validation set, scores were 8% (95% CI 3–16) for score 1, 27% (20–34) for score 2, and 46% (33–58) for score 3 (p<0·0001). Conversely, the response to primary GVHD treatment within 28 days decreased as the GVHD score increased 86% for score 1, 67% for score 2, and 46% for score 3 in the multicentre validation set, p<0·0001). Interpretation Biomarker-based scores can be used to guide risk-adapted therapy at the onset of acute GVHD. High risk patients with a score of 3 are candidates for intensive primary therapy, while low risk patients with a score of 1 are candidates for rapid tapers of systemic steroid therapy. Funding The National Cancer Institute, the National Heart, Lung, and Blood Institute, the National Institute of Allergy and Infectious Diseases, the Doris Duke Charitable Fund, the American Cancer Society, and the Judith Devries Fund.
  • Editor: England: Elsevier Ltd
  • Idioma: Inglês
Links
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.